Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

SAVA

Cassava Sciences Inc

Feb 06 • 04:00PM ET

2.03

+0.14 7.41 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB LLY AVXL SRPT ANVS ACLX PRTA AXSM FATE XERS

| Held by: VTI VXF VHT IWC AVSC DFAS QQQS BTEC DCOR IBRN

Index	-	P/E	-	EPS (ttm)	-2.20	Insider Own	11.72%	Shs Outstand	48.31M	Perf Week	2.01%
Market Cap	98.06M	Forward P/E	-	EPS next Y	-1.22	Insider Trans	9.49%	Shs Float	42.65M	Perf Month	-6.88%
Enterprise Value	-8.02M	PEG	-	EPS next Q	-0.30	Inst Own	28.31%	Short Float	16.82%	Perf Quarter	-33.44%
Income	-106.03M	P/S	-	EPS this Y	-32.19%	Inst Trans	5.70%	Short Ratio	7.45	Perf Half Y	-7.31%
Sales	0.00M	P/B	1.20	EPS next Y	36.79%	ROA	-59.99%	Short Interest	7.17M	Perf YTD	2.53%
Book/sh	1.69	P/C	0.92	EPS next 5Y	-	ROE	-85.44%	52W High	4.98 -59.24%	Perf Year	-16.80%
Cash/sh	2.20	P/FCF	-	EPS past 3/5Y	-21.17% -40.61%	ROIC	-129.99%	52W Low	1.15 76.52%	Perf 3Y	-92.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.22% 5.71%	Perf 5Y	-91.17%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-505.96%	Oper. Margin	-	ATR (14)	0.13	Perf 10Y	-81.99%
Dividend Ex-Date	Dec 13, 2012	Quick Ratio	2.27	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	44.82	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.27	EPS Q/Q	61.59%	SMA20	-1.62%	Beta	-0.81	Target Price	8.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-16.52%	Rel Volume	0.61	Prev Close	1.89
Employees	30	LT Debt/Eq	0.00	Earnings	Nov 12 BMO	SMA200	-17.83%	Avg Volume	962.41K	Price	2.03
IPO	Jul 14, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	18.52% -	Trades		Volume	582,727	Change	7.41%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-26-24	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-08-24	Upgrade	H.C. Wainwright	Neutral → Buy	$116
Jul-01-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-16-22	Downgrade	B. Riley Securities	Buy → Neutral	$44
Jul-15-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$100
Jul-07-21	Reiterated	Maxim Group	Buy	$80 → $190
Apr-27-21	Initiated	B. Riley Securities	Buy	$78
Feb-16-21	Reiterated	H.C. Wainwright	Buy	$20 → $66
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight	$24
Sep-23-20	Upgrade	H.C. Wainwright	Neutral → Buy	$20
May-18-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-15-20	Downgrade	Maxim Group	Buy → Hold
Jan-10-20	Reiterated	Maxim Group	Buy	$3 → $12

Show Previous Ratings

Jan-13-26 08:00AM	Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's Disease (GlobeNewswire)
Dec-24-25 11:51AM	HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Dec-23-25 08:00AM	Cassava Announces Agreement to Settle Securities Class Action Litigation (GlobeNewswire) -7.56%
Nov-25-25 07:39AM	Cassava Pops After CEO Buys 150,000 Shares (GuruFocus.com)
Nov-12-25 08:00AM	Cassava Reports Q3 2025 Financials Results and Provides Business Update (GlobeNewswire)
04:05PM	Loading…
Oct-22-25 04:05PM	Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire) -7.04% +5.68%
08:00AM	Cassava Sciences Appoints Dawn C. Bir to the Board of Directors (GlobeNewswire)
Sep-24-25 04:58AM	Cassava, Accenture to deploy sovereign AI solutions across Africa (Verdict)
Sep-23-25 12:13PM	Cassava Boss Buys Big As Stock Collapses (GuruFocus.com) +46.98%
Aug-25-25 08:00AM	Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-14-25 07:30AM	Cassava Reports Q2 2025 Financials Results and Provides Business Update (GlobeNewswire) +5.70%
Aug-07-25 07:30AM	Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer (GlobeNewswire) -6.41%
Aug-04-25 07:30AM	Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy (GlobeNewswire) +8.02%
Jun-30-25 07:00AM	Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting (GlobeNewswire)
May-08-25 08:00AM	Cassava Reports Q1 2025 Financials Results, Provides Business Update (GlobeNewswire) +8.97%
07:30AM	Loading…
May-01-25 07:30AM	Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC (GlobeNewswire)
07:30AM	Cassava Appoints Angelique Bordey, PhD, to Enhance Preclinical Program in TSC (GlobeNewswire)
Apr-21-25 04:30PM	Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development (GlobeNewswire) +8.90%
Apr-01-25 09:35AM	Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround (Zacks) -8.00%
Mar-31-25 10:00AM	Is the Future Bleak for SAVA Stock Following Another Setback? (Zacks) -9.09%
Mar-26-25 10:02AM	Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More (Zacks) -7.89%
07:43AM	SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study (Zacks)
Mar-25-25 08:05AM	Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data (GlobeNewswire) -32.14%
Mar-20-25 06:18PM	Cassava Sciences: Downside From Alzheimer's Results Still Possible Despite New Developments (SeekingAlpha)
Mar-05-25 11:20AM	H.C. Wainwright focused on what results from Cassavas ReFocus-ALZ might reveal (TipRanks)
Mar-03-25 07:30AM	Cassava Sciences Reports 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-25 07:00AM	Cassava Sciences Licenses Simufilam Method of Treatment Patent (GlobeNewswire) +13.04%
Jan-16-25 01:56PM	Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights SAVA (GlobeNewswire)
Jan-13-25 12:15PM	Cassava Sciences, Inc. Sued for Securities Law Violations Investors Should Contact Levi and Korsinsky Before February 10, 2025 to Discuss Your Rights SAVA (GlobeNewswire)
Jan-07-25 04:30PM	Cassava Sciences Provides a Business Update (GlobeNewswire) -6.46%
05:45AM	Loading…
Dec-27-24 05:45AM	Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi and Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA (PR Newswire)
Dec-16-24 02:55PM	Cassava Sciences, Inc. Sued for Securities Law Violations Investors Should Contact Levi and Korsinsky for More Information SAVA (GlobeNewswire)
Nov-25-24 04:15PM	Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops (Investor's Business Daily) -83.78% -10.94%
03:57PM	Cassava Sciences plummets over 80% on Alzheimer's trial fail (Yahoo Finance Video)
09:19AM	Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study (Investopedia)
07:30AM	Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints (GlobeNewswire)
Nov-24-24 08:01PM	Cassava Sciences to Hold Corporate Update on November 25th (GlobeNewswire)
Nov-18-24 08:30AM	Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer (GlobeNewswire)
Nov-07-24 07:55AM	Cassava Sciences Reports Q3 2024 Financial and Operating Results (GlobeNewswire)
Oct-31-24 08:30AM	Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024 (GlobeNewswire)
Oct-17-24 09:19PM	Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge (Insider Monkey)
Oct-09-24 08:29AM	Cassava Sciences Advances Alzheimers Trials Amid SEC Settlement (TipRanks)
Sep-27-24 03:36PM	Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims (Yahoo Finance Video) -10.62%
10:10AM	Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims (Investopedia)
Sep-26-24 06:15PM	Cassava Sciences Resolves SEC Investigation (GlobeNewswire)
Sep-24-24 08:30AM	Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials (GlobeNewswire) +9.54%
Sep-09-24 08:30AM	Cassava Sciences Names Rick Barry as Chief Executive Officer (GlobeNewswire)
Sep-03-24 08:31AM	Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-17-24 10:44PM	Silicon Motion Technology Corporation (SAVA): Evaluating Its Position Among Top Debt-Free Stocks (Insider Monkey)
08:22AM	7 Best Debt Free Stocks To Buy (Insider Monkey)
Aug-08-24 08:00AM	Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates (GlobeNewswire) -13.84%
Aug-06-24 10:00AM	Cassava Sciences News: Why Is SAVA Stock Trending Today? (InvestorPlace) -13.08%
Aug-05-24 09:01AM	Cassava Sciences Mourns the Death of Board Member Sanford Sandy Robertson (GlobeNewswire) +20.51%
Aug-01-24 08:30AM	Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET (GlobeNewswire) +5.72%
Jul-30-24 08:15AM	Cassava Sciences Announces Expansion of Open-Label Extension Trials (GlobeNewswire)
Jul-17-24 12:26PM	SOUN Stock: Sports Bar Chain Rolls Out Voice Tech From SoundHound AI (InvestorPlace) -29.27%
08:00AM	Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives (GlobeNewswire)
Jul-08-24 04:45PM	3 Healthcare Stocks to Sell in July Before They Crash & Burn (InvestorPlace) +17.38%
Jul-05-24 07:30AM	3 Biotech Stocks to Sell in July Before They Crash & Burn (InvestorPlace) -5.15%
Jul-04-24 07:47AM	Jim Cramer's Latest Stock Portfolio: Top 10 Recommendations (Insider Monkey)
Jul-01-24 03:54PM	Cassava forms committee after US probe, researcher fraud (Yahoo Finance Video)
01:30PM	Stocks to Watch Monday: Chewy, Boeing, NIO, Cassava Sciences (The Wall Street Journal)
11:20AM	Planet Labs Layoffs 2024: What to Know About the Latest Planet Job Cuts (InvestorPlace)
10:40AM	SAVA Stock Alert: Former Cassava Science Advisor Charged With Fraud (InvestorPlace)
Jun-28-24 06:14PM	Cassava Sciences Adviser Indicted on Fraud Charges (The Wall Street Journal) -34.83%
03:58PM	Cassava Sciences Issues Statement on Former Science Advisor (GlobeNewswire)
Jun-27-24 03:38PM	Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich (InvestorPlace)
May-23-24 09:55AM	Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
May-10-24 08:53PM	SAVA Stock Earnings: Cassava Sciences Beats EPS for Q1 2024 (InvestorPlace)
04:02PM	Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam (GlobeNewswire)
May-08-24 11:00AM	Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution (GlobeNewswire)
May-01-24 09:10AM	Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ (GlobeNewswire)
Apr-30-24 01:16PM	Stock Market Crash Warning: Don't Get Caught Holding These 3 Biotech Stocks (InvestorPlace)
Apr-15-24 09:20AM	Redemption Date Announced for Warrants (GlobeNewswire) -12.04%
Mar-25-24 09:13AM	Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials (GlobeNewswire)
Mar-13-24 10:45AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava (PR Newswire)
Mar-04-24 09:15AM	Cassava Sciences Announces Virtual Presentation at the AD/PD 2024 International Conference (GlobeNewswire)
Feb-28-24 09:14AM	Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates (GlobeNewswire)
Feb-23-24 11:30AM	CASSAVA SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Feb-08-24 10:39AM	Cassava Sciences (SAVA) Stock Pops on Positive Results in Simufilam Trial (InvestorPlace)
Feb-07-24 09:08AM	No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months (GlobeNewswire) +7.35%
Feb-05-24 02:35PM	Cassava Sciences Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Jan-05-24 11:46AM	New SAVAW Warrants Are Trading After Cassava Sciences' Distribution (InvestorPlace)
09:12AM	Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders (GlobeNewswire)
Dec-26-23 05:06AM	3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street (Motley Fool)
Dec-15-23 06:06PM	Why Cassava Sciences Stock Zoomed 21% Higher This Week (Motley Fool)
Dec-13-23 11:10AM	Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days (Investor's Business Daily)
Dec-12-23 02:02PM	Why Is Cassava Sciences (SAVA) Stock Up 15% Today? (InvestorPlace) +5.96%
09:13AM	Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders (GlobeNewswire)
Dec-08-23 07:31PM	Why Cassava Sciences Stock Soared Today (Motley Fool) +17.37% +13.57%
Dec-07-23 04:01PM	Cassava Sciences Appoints Three New Members to its Board of Directors (GlobeNewswire)
Nov-14-23 09:53PM	7 High-Risk, High-Reward Stocks for the Extreme Contrarian (InvestorPlace) +13.90%
Nov-07-23 09:39AM	Cassava Sciences Inc (SAVA) Reports Q3 2023 Financial Results (GuruFocus.com)
09:01AM	Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results (GlobeNewswire)
Nov-06-23 09:15AM	Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer's Disease (GlobeNewswire) -5.81%
Oct-31-23 08:15AM	1 Big Red Flag to Fear When a Stock Is Down (Motley Fool) +6.39%
Oct-25-23 09:15AM	MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA) (GlobeNewswire) +25.80%
Oct-19-23 09:59AM	7 Stocks That Are Heading for a Train Wreck (InvestorPlace) +5.32%
Oct-16-23 07:01PM	Is This The End Of Naked Short Selling? (Oilprice.com) -14.94% +13.21%
05:26PM	SAVA Stock Continues to Plunge on Misconduct Allegations (InvestorPlace)

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anderson Robert Eugene Jr	Director	Nov 24 '25	Buy	2.90	8,600	24,940	8,600	Nov 25 04:06 PM
Barry Richard	President & CEO	Nov 20 '25	Buy	2.76	150,000	414,000	938,060	Nov 24 04:02 PM
Barry Richard	President & CEO	Nov 19 '25	Buy	2.75	73,385	201,809	788,060	Nov 20 05:39 PM
Cook Robert Christopher	Chief Operating & Legal Office	Sep 30 '25	Buy	2.91	13,725	39,940	13,725	Oct 02 04:44 PM
Barry Richard	President & CEO	Sep 22 '25	Buy	2.28	7,172	16,352	714,675	Sep 23 04:06 PM
Barry Richard	President & CEO	Sep 18 '25	Buy	2.24	190,633	426,424	660,195	Sep 22 04:07 PM
Barry Richard	President & CEO	Sep 19 '25	Buy	2.29	47,308	108,319	707,503	Sep 22 04:07 PM

Open in Screener

SRPT

Sarepta Therapeutics Inc

Feb 06 • 04:00PM ET

18.50

+1.47 8.63 %

Healthcare • Biotechnology • USA • NASD

SRPT Sarepta Therapeutics Inc daily Stock Chart

Peers: VRTX BMRN ALNY IONS PFE PTCT EXEL PRTA BLUE RDUS

| Held by: IJR VTI FBT XBI VB VBK VXF SPSM FXH IBB

Index	-	P/E	-	EPS (ttm)	-2.89	Insider Own	5.88%	Shs Outstand	104.77M	Perf Week	-9.05%
Market Cap	1.94B	Forward P/E	9.59	EPS next Y	1.93	Insider Trans	-0.21%	Shs Float	98.62M	Perf Month	-21.14%
Enterprise Value	2.34B	PEG	1.70	EPS next Q	-1.20	Inst Own	87.17%	Short Float	21.58%	Perf Quarter	-0.91%
Income	-271.51M	P/S	0.80	EPS this Y	-324.40%	Inst Trans	2.44%	Short Ratio	6.34	Perf Half Y	3.01%
Sales	2.41B	P/B	1.47	EPS next Y	139.42%	ROA	-7.66%	Short Interest	21.28M	Perf YTD	-14.03%
Book/sh	12.60	P/C	2.28	EPS next 5Y	5.64%	ROE	-21.37%	52W High	119.26 -84.49%	Perf Year	-84.46%
Cash/sh	8.12	P/FCF	-	EPS past 3/5Y	- -	ROIC	-10.56%	52W Low	10.41 77.63%	Perf 3Y	-85.20%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.42% 37.94%	Gross Margin	74.19%	Volatility	8.51% 7.27%	Perf 5Y	-79.31%
Dividend TTM	-	EV/Sales	0.97	EPS Y/Y TTM	-311.26%	Oper. Margin	-3.56%	ATR (14)	1.44	Perf 10Y	55.07%
Dividend Ex-Date	-	Quick Ratio	1.78	Sales Y/Y TTM	47.15%	Profit Margin	-11.25%	RSI (14)	39.56	Recom	2.77
Dividend Gr. 3/5Y	- -	Current Ratio	2.95	EPS Q/Q	-630.03%	SMA20	-12.14%	Beta	0.43	Target Price	21.43
Payout	0.00%	Debt/Eq	0.95	Sales Q/Q	-14.52%	SMA50	-13.52%	Rel Volume	0.94	Prev Close	17.03
Employees	1372	LT Debt/Eq	0.95	Earnings	Nov 03 AMC	SMA200	-23.55%	Avg Volume	3.36M	Price	18.50
IPO	Jun 04, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	-147.59% 18.94%	Trades		Volume	3,167,783	Change	8.63%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Equal Weight	$20
Dec-09-25	Initiated	Wedbush	Outperform	$32
Nov-05-25	Upgrade	Mizuho	Neutral → Outperform	$26
Sep-22-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$50
Jul-29-25	Upgrade	Oppenheimer	Perform → Outperform	$37
Jul-29-25	Upgrade	JP Morgan	Underweight → Neutral	$24
Jul-29-25	Upgrade	Barclays	Underweight → Equal Weight	$22
Jul-29-25	Reiterated	H.C. Wainwright	Sell	$5
Jul-29-25	Initiated	Bernstein	Mkt Perform	$13
Jul-28-25	Downgrade	Barclays	Equal Weight → Underweight	$10
Jul-25-25	Downgrade	JP Morgan	Neutral → Underweight
Jul-24-25	Initiated	Citigroup	Sell	$7
Jul-23-25	Downgrade	BofA Securities	Neutral → Underperform	$10
Jul-22-25	Downgrade	Barclays	Overweight → Equal Weight	$18
Jul-21-25	Downgrade	UBS	Buy → Neutral	$12
Jul-21-25	Downgrade	Needham	Hold → Underperform
Jul-21-25	Downgrade	Mizuho	Outperform → Neutral	$14
Jul-21-25	Downgrade	Leerink Partners	Outperform → Market Perform	$10
Jul-21-25	Downgrade	Deutsche Bank	Buy → Hold	$9
Jul-18-25	Downgrade	Needham	Buy → Hold

Show Previous Ratings

Feb-06-26 12:04AM	Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... (GuruFocus.com) +8.63%
Feb-05-26 08:06PM	Arrowhead Pharmaceuticals Q1 Earnings Call Highlights (MarketBeat) -13.68%
Jan-31-26 12:02AM	Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags (MarketBeat)
Jan-27-26 10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
06:45AM	Sarepta eyes Elevidys sales comeback with positive Phase III data (Clinical Trials Arena)
04:17PM	Loading…
Jan-26-26 04:17PM	Sarepta Pops On Elevidys Data; But Will It Save The Embattled Gene Therapy? (Investor's Business Daily) +7.90%
02:49PM	Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. (Barrons.com)
01:26PM	Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday? (Benzinga)
12:00PM	Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
11:56AM	Stocks to Watch Monday: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)
11:36AM	These Stocks Are Todays Movers: USA Rare Earth, CoreWeave, Micron, Intel, Newmont, IonQ, Sarepta, and More (Barrons.com)
11:23AM	Sarepta Stock Climbs 11% on Positive Three-Year Study Results for Elevidys (Barrons.com)
09:26AM	Sarepta Says Elevidys Slows Duchenne Progression After Three Years (Benzinga)
09:15AM	Is KROS' KER-065 the Next Breakthrough in DMD Space? (Zacks)
08:53AM	Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys (Barrons.com)
08:00AM	Loading…
08:00AM	Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients (Business Wire)
06:46AM	Sarepta, battling slowing sales, claims Duchenne gene therapys impact grows with time (BioPharma Dive)
05:36AM	Stock Market Today: Dow Jones, S&P 500 Futures Slip As Investors Brace For Mega-Cap Earnings-Brand Engagement, Nucor In Focus (Benzinga)
Jan-23-26 04:05PM	Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy (Business Wire)
Jan-21-26 10:50PM	2 Beaten-Down Stocks That Could Sink Even More in 2026 (Motley Fool)
Jan-16-26 09:08AM	Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? (Zacks)
Jan-15-26 09:14AM	KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? (Zacks) -6.54%
Jan-13-26 08:08AM	JPM26: Sarepta CEO touts avalanche of Elevidys data amid 2025 safety woes (Pharmaceutical Technology)
Jan-12-26 04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily) -11.29%
12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga)
11:58AM	Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues (Business Wire)
Jan-05-26 08:30AM	Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-25 05:20PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-18-25 01:13PM	Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory (Insider Monkey)
Dec-11-25 07:00AM	Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027 (Business Wire)
11:30AM	Loading…
Dec-03-25 11:30AM	Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report? (Zacks) +6.69%
Dec-02-25 08:00AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
Nov-25-25 02:17PM	Trump Media Stock and 11 More Tax-Loss Victims to Avoid Until 2026 (Barrons.com)
01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)
12:07PM	Trump Media and 11 More Stocks to Avoid Until 2026 (Barrons.com)
08:57AM	Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne (Business Wire)
Nov-24-25 07:30AM	Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics (Business Wire) +6.90%
Nov-17-25 09:32AM	FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings (Zacks) -6.75%
Nov-15-25 09:35AM	2 Beaten-Down Stocks to Avoid Right Now (Motley Fool)
Nov-14-25 03:14PM	FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths (Associated Press Finance) +5.56%
02:54PM	Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information (Business Wire)
Nov-06-25 05:43AM	Sarepta (SRPT) Soars 15% on Bullish Rating (Insider Monkey) -5.52%
Nov-05-25 10:21AM	Mizuho upgrades Sarepta on confidence in Elevidys uptake (Investing.com) +15.25%
03:31AM	Sarepta Stock Tumbles 34% After Earnings Report. Why Shares Crashed. (Barrons.com)
Nov-04-25 04:51PM	These Stocks Moved the Most Today: Palantir, Uber, Sarepta, Tesla, Norwegian Cruise Line, Hertz, AMD, and More (Barrons.com) -33.74%
04:14PM	Sarepta Loses A Third Of Its Value On Failed Tests, Gene Therapy Outlook (Investor's Business Daily)
02:39PM	These Stocks Are Moving the Most Today: Palantir, Uber, Sarepta, Tesla, Norwegian Cruise Line, Hertz, AMD, and More (Barrons.com)
01:46PM	SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure (Zacks)
11:54AM	Top Stock Movers Now: Palantir, Sarepta Therapeutics, Denny's, and More (Investopedia)
11:11AM	Sarepta Therapeutics Stock Tumbles After Trial Data (Schaeffer's Research)
10:59AM	Pfizer & Novo boost Metsera bids, Hertz stock skyrockets (Yahoo Finance Video)
10:14AM	Sarepta Loses Almost A Third Of Its Value On Failed Tests, Gene Therapy Outlook (Investor's Business Daily)
09:58AM	Sarepta Stock Tumbles 35% After Earnings Report. Why Shares Are Crashing. (Barrons.com)
09:39AM	Stocks to Watch Tuesday: Palantir, Sarepta, Tesla (The Wall Street Journal)
09:30AM	Sarepta Therapeutics (SRPT) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:05AM	Sarepta Earnings Beat Expectations. Why the Stock Is Down 40%. (Barrons.com)
07:39AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:13AM	Two of Sareptas DMD drugs fail to meet primary endpoint in confirmatory trial (Clinical Trials Arena)
06:20AM	Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking. (Barrons.com)
05:57AM	Palantir stock slides after earnings, and other early market movers (MarketWatch)
05:31AM	These Stocks Are Moving the Most Today: Palantir, Sarepta, Amazon, AMD, Pfizer, and More (Barrons.com)
04:00AM	Sarepta Duchenne drugs come up short in confirmatory test (BioPharma Dive)
12:00AM	Sarepta Therapeutics Inc (SRPT) Q3 2025 Earnings Call Highlights: Resilient Revenue Amidst ... (GuruFocus.com)
Nov-03-25 06:26PM	Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success (MarketWatch)
05:20PM	Sarepta Therapeutics (SRPT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:23PM	Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory Tests (Investor's Business Daily)
04:16PM	Sarepta Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE (Business Wire)
Oct-28-25 11:44AM	Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-27-25 04:05PM	Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results (Business Wire)
Oct-21-25 06:46AM	Tradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF (PR Newswire)
Oct-03-25 02:14PM	Sarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial Results (Insider Monkey)
08:30AM	Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress (Business Wire)
Oct-02-25 02:39PM	How to make money from tax-loss selling between now and the end of the year (MarketWatch) +15.68%
05:31AM	FDA leaders are acting political, says ex-agency chief counsel (Pharmaceutical Technology)
Sep-30-25 06:00PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-28-25 04:38AM	Street Calls of the Week (Investing.com)
Sep-15-25 08:30AM	Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth (PR Newswire)
Sep-05-25 09:30AM	2 Beaten-Down Stocks to Avoid Right Now (Motley Fool)
09:00AM	Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year (Business Wire)
Sep-03-25 07:27AM	Sarepta Therapeutics (SRPT) Fell Despite Reporting Good Results (Insider Monkey)
Aug-28-25 08:21AM	Cell and gene therapies on correction course but not sinking (Pharmaceutical Technology)
Aug-26-25 06:15PM	Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 (PR Newswire)
Aug-23-25 11:33AM	Credit Fuels the AI Boom and Fears of a Bubble (Bloomberg)
Aug-21-25 12:13PM	Walmart weighs on Dow, Sarepta debt restructuring (Yahoo Finance Video)
09:33AM	Sarepta Gets Breathing Room in $700 Million Debt Restructure (Bloomberg)
07:00AM	Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027 (Business Wire)
06:56AM	Sarepta pushes off debt payments in bid to regain financial footing (BioPharma Dive)
Aug-20-25 11:37PM	Jim Cramer on Sarepta Therapeutics: "If it Goes Up, You Gotta Do Some Selling" (Insider Monkey)
11:02AM	Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. (Barrons.com)
Aug-18-25 09:03AM	Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your Rights - Contact Levi & Korsinsky Before August 25, 2025 (Newsfile)
07:00AM	How the Moms and Dads of Patients Won Sareptas Drug a Reprieve (Bloomberg)
Aug-15-25 09:15AM	Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT (PR Newswire) +7.44%
Aug-14-25 09:00PM	Lightning Round: I don't have a positive outlook on Sarepta, says Jim Cramer (CNBC TV)
04:18PM	Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives (Investor's Business Daily)
11:41AM	Sarepta Sells Biotech Stake to Raise Cash as Elevidys Troubles Hit Home (Barrons.com)
11:24AM	Sarepta Sells Arrowhead Stake to Fund Milestone Payment (Zacks)
07:29AM	Sarepta sells Arrowhead shares as partnership, debt payments loom (BioPharma Dive)
Aug-13-25 04:12PM	Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment (Business Wire) +8.51%
04:10PM	Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics (Business Wire)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nicaise Claude	Director	Jan 29 '26	Option Exercise	13.71	10,500	143,955	38,312	Jan 29 08:05 PM
BEHRENS M KATHLEEN	Director	Jan 27 '26	Option Exercise	13.71	10,500	143,955	203,976	Jan 29 08:04 PM
Estepan Ian Michael	Chief Operating Officer	Dec 16 '25	Sale	22.31	13,187	294,202	193,300	Dec 18 08:05 PM
IAN M ESTEPAN	Officer	Dec 16 '25	Proposed Sale	22.31	13,187	294,145		Dec 16 05:05 PM
Sarepta Therapeutics, Inc.	Shareholder	Aug 13 '25	Proposed Sale	19.99	9,265,312	185,213,587		Aug 13 08:55 PM
Barry Richard	Director	May 16 '25	Option Exercise	32.63	12,350	402,981	2,966,667	May 19 07:32 AM
Barry Richard	Director	May 13 '25	Option Exercise	19.23	20,246	389,359	2,954,317	May 15 07:00 AM
Nicaise Claude	Director	Mar 12 '25	Option Exercise	25.18	9,746	245,404	30,303	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Sale	99.64	2,491	248,203	27,812	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Proposed Sale	99.65	2,491	248,226		Mar 12 05:33 PM

SAVA

Cassava Sciences Inc

SRPT

Sarepta Therapeutics Inc

Upgrade your FINVIZ experience